Eltrombopag for thrombocytopenia in CML

Study title

Eltrombopag for low platelet count associated with TKI in CML [USA]

Scientific title

Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) and myelofibrosis (MF) (ClinicalTrials.gov NCT01428635)

Indication and most important inclusion criteria

This study includes patients 18 years and older diagnosed with CML in chronic phase. Patients must have been receiving an FDA-approved tyrosine kinase inhibitor (TKI) for at least 3 months.
Patients must have a decrease of platelets in the blood (known as "thrombocytopenia"), grade 3, that is recurrent (at least two episodes) or requiring dose reductions of the tyrosine kinase inhibitor.

Short description of intervention

Patients with CML receiving tyrosine kinase inhibitors who develop persistent or profound decrease of platelets ("thrombocytopenia") are offered eltrombopag together with continuation of their TKI. The goal of this study is to learn if eltrombopag can improve the platelet count in the blood.

Type of study

Other studies
In a single country

Current status

Recruiting

Study sponsor

MD Anderson Cancer Center

Scientific lead / contact

Jorge Cortes

Principal investigator

Gautam Borthakur

Additional information

Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health

Study centers / principal investigators

United States

MD Anderson Cancer Center
University of Texas
Houston, Texas